Tudor Investment Corp’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,236
| Closed | -$213K | – | 3223 |
|
|
2021
Q3 | $213K | Sell |
1,236
-19,467
| -94% | -$2.55M | ﹤0.01% | 2271 |
|
|
2021
Q2 | $2.6M | Buy |
+20,703
| New | +$2.61M | 0.05% | 455 |
|
|
2019
Q4 | – | Sell |
-13,649
| Closed | -$539K | – | 1453 |
|
|
2019
Q3 | $539K | Buy |
+13,649
| New | +$592K | 0.02% | 695 |
|
|
2018
Q1 | – | Sell |
-8,297
| Closed | -$352K | – | 1335 |
|
|
2017
Q4 | $352K | Sell |
8,297
-71,165
| -90% | -$2.67M | 0.01% | 754 |
|
|
2017
Q3 | $2.97M | Buy |
79,462
+66,662
| +521% | +$2.31M | 0.08% | 151 |
|
|
2017
Q2 | $389K | Buy |
12,800
+3,695
| +41% | +$107K | 0.01% | 665 |
|
|
2017
Q1 | $241K | Buy |
9,105
+716
| +9% | +$18.9K | 0.01% | 1134 |
|
|
2016
Q4 | $214K | Buy |
8,389
+1,631
| +24% | +$51.7K | 0.01% | 1194 |
|
|
2016
Q3 | $245K | Sell |
6,758
-7,382
| -52% | -$245K | 0.01% | 1139 |
|
|
2016
Q2 | $480K | Buy |
14,140
+3,044
| +27% | +$99K | 0.01% | 864 |
|
|
2016
Q1 | $293K | Buy |
11,096
+6,660
| +150% | +$194K | 0.01% | 1308 |
|
|
2015
Q4 | $216K | Sell |
4,436
-4,033
| -48% | -$145K | 0.01% | 1411 |
|
|
2015
Q3 | $211K | Buy |
+8,469
| New | +$255K | 0.01% | 1315 |
|
Tudor Investment Corp's XLRN Position: Q4 2021 in Review
Tudor Investment Corp sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,236 shares — an estimated $213K sold.
Tudor Investment Corp first reported a position in XLRN in Q3 2015 and held it in 13 quarters. The position peaked at $2.97M in Q3 2017. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Tudor Investment Corp reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Tudor Investment Corp sold 1,236 Acceleron Pharma shares in Q4 2021, an estimated $213K.
- Tudor Investment Corp first reported a position in Acceleron Pharma in Q3 2015 and held it in 13 quarters.
- Tudor Investment Corp's Acceleron Pharma position peaked at $2.97M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.